BMC Cancer (Oct 2006)

High Smac/DIABLO expression is associated with early local recurrence of cervical cancer

  • Maldonado Vilma,
  • De la Garza Jaime G,
  • Espinosa Magali,
  • Cantu David,
  • Perez Delia,
  • Garcia Francisco J,
  • Arellano-Llamas Abril,
  • Melendez-Zajgla Jorge

DOI
https://doi.org/10.1186/1471-2407-6-256
Journal volume & issue
Vol. 6, no. 1
p. 256

Abstract

Read online

Abstract Background In a recent pilot report, we showed that Smac/DIABLO mRNA is expressed de novo in a subset of cervical cancer patients. We have now expanded this study and analyzed Smac/DIABLO expression in the primary lesions in 109 cervical cancer patients. Methods We used immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections to analyze Smac/DIABLO expression in the 109 primary lesions. Seventy-eight samples corresponded to epidermoid cervical cancer and 31 to cervical adenocarcinoma. The median follow up was 46.86 months (range 10–186). Results Smac/DIABLO was expressed in more adenocarcinoma samples than squamous tumours (71% vs 50%; p = 0.037). Among the pathological variables, a positive correlation was found between Smac/DIABLO immunoreactivity and microvascular density, a marker for angiogenesis (p = 0.04). Most importantly, Smac/DIABLO immunoreactivity was associated with a higher rate of local recurrence in squamous cell carcinoma (p = 0.002, log rank test). No association was found between Smac/DIABLO and survival rates. Conclusion Smac/DIABLO expression is a potential marker for local recurrence in cervical squamous cell carcinoma patients.